医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nippon Soda and Syngenta Enter into Global Licensing Agreement for Novel Seed Treatment Technology

2018年02月26日 PM04:00
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

TOKYO & BASEL, Switzerland

Nippon Soda and Syngenta announced today a global seed treatment licensing agreement for PICARBUTRAZOX, a new active ingredient from a novel chemical class discovered by Nippon Soda. It shows robust and reliable performance for the control of Pythium damping off and seedling blight diseases under many different cropping systems.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180225005248/en/

Tackling Pythium allows farmers to adopt reduced or no-tillage cropping systems protecting the soil, avoid the costs of having to replant and get benefits from better germination, strong stand establishment and higher yields.

Ioana Tudor, Global Head of Syngenta Seedcare, said “We are proud that Nippon Soda has partnered with Syngenta Seedcare to bring this exciting technology to the seed industry and farmers globally. PICARBUTRAZOX, with its novel mode of action will strengthen Syngenta’s leading Pythium control portfolio Mefenoxam and Azoxystrobin Technology in corn, soybeans, canola, oilseed rape, cereals and other crops.”

Chinami Yokota, Nippon Soda Director of Development Department, said “Nippon Soda has strong research capabilities and it was an excellent decision to choose Syngenta Seedcare as a leader in the seed treatment market to broaden the use of PICARBUTRAZOX beyond foliar application.”

First registrations of PICARBUTRAZOX on seed treatment are expected in the United States and Canada in 2019.

About Syngenta

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 27,500 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit www.syngenta.com and www.twitter.com/Syngenta.

Find out more about Syngenta Seedcare at https://www.syngentaseedcare.com/.

About Nippon Soda

Since our founding in 1920, Nippon Soda has accumulated unique technologies and know-how, and provided highly functional and high-value-added chemical products in such diverse fields as agriculture, pharmaceuticals and specialty chemicals. Furthermore, as a company that handles chemical substances, we have always been mindful of the doctrine of responsible care and have driven business activities with attention to the environment, safety and health. Going forward, Nippon Soda will contribute to the building of a rich society that realizes the dreams of the next generation through innovative technologies and products.

For additional information, visit the company’s website at www.nippon-soda.co.jp.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180225005248/en/

CONTACT

Syngenta International AG
Media Office
Telephone: +41
61 323 23 23
Fax: +41 61 323 24 24
www.syngenta.com
or
Syngenta
Media:

Switzerland
Andrew McConville, +41 61 323 0618
media.relations@syngenta.com
or
USA
Paul
Minehart, +1 202-737-8913
or
Syngenta Analyst/Investor:
Andrew
McConville
Switzerland: +41 61 323 0618
USA: +1 202-737-6521
or
Nippon
Soda Co., Ltd.

Stakeholder Relations Group
Telephone: +81
3 3245 6054
Fax: +81 3 3245 6238
www.nippon-soda.co.jp
or
Nippon
Soda Media:

Japan
Satoshi Takeuchi, +81 3 3245 6053
info@nippon-soda.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究